For the remainder of the examination, assume that the develo…
For the remainder of the examination, assume that the development team ultimately chooses a randomized, double-blind, placebo-controlled Phase 3 superiority trial comparing STAT-509 with placebo over 24 weeks. Participants in both treatment groups may continue their usual acute migraine medications.
Read Details